子宫内膜癌:分子标志物与晚期疾病的管理
子宫内膜癌是美国最常见的妇科癌症,近10年死亡率每年上升约1.4%。治疗传统上基于分期和组织学,但同分期同组织学的癌症具有不同的分子和基因组特征。基于肿瘤分子谱的首个组织不可知疗法今年获FDA批准;派姆单抗(抗PD-1)获批用于所有DNA错配修复缺陷的实体瘤,可能使20-30%的晚期子宫内膜癌患者获益。单药靶向治疗活性有限,识别有效预测靶向治疗反应的生物标志物仍是挑战。
要点
- 子宫内膜癌近10年死亡率每年上升约1.4%。
- 派姆单抗(抗PD-1)获批用于DNA错配修复缺陷实体瘤,可能使20-30%晚期子宫内膜癌患者获益。
- 单药靶向治疗活性有限,生物标志物预测靶向治疗反应仍是挑战。
核心结论
- 同分期同组织学的子宫内膜癌具有不同的分子和基因组特征,基于分子谱的精准医学正在发展。
研究设计与样本
- 综述总结了晚期和/或复发子宫内膜癌治疗选择的重要试验,以及理解子宫内膜癌独特分子和基因组谱的研究。
主要发现
- 近10年子宫内膜癌死亡率每年上升约1.4%。
- 基于肿瘤分子谱的首个组织不可知疗法今年获FDA批准。
- 派姆单抗(抗PD-1)获批用于所有DNA错配修复缺陷的实体瘤,可能使20-30%的晚期子宫内膜癌患者获益。
- 单药靶向治疗活性有限。
- 识别有效预测靶向治疗反应的生物标志物仍是挑战。
局限性
- 单药靶向治疗活性有限。
- 识别有效预测靶向治疗反应的生物标志物仍是挑战。
- 如何解释和利用子宫内膜癌基因组特征的数据仍在探索中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endometrial cancer is the most prevalent gynecologic cancer in the United States. Over the last 10 years, death rates from endometrial cancer have been rising about 1.4% per year. Traditionally endometrial cancer treatment has been driven by stage and histology. Recent studies have, however, shown that cancers of the same stage and histology have very distinct molecular and genomic profiles. Translational research is progressing rapidly and endometrial cancer-specific precision medicine is evolving. The first tissue agnostic therapy based on the molecular profile of the tumor was approved by the FDA this year. The approval of immune checkpoint inhibitor, pembrolizumab (anti-PD-1), for all solid tumors with defective DNA mismatch repair, could benefit 20-30% of patients with advanced endometrial cancer. Other genomic changes and molecular markers in endometrial cancer, such as hormone receptor status, could lead to more tailored therapy in the future. Pre-clinical and clinical investigations of targeted therapies suggest efficacy for some agents. Single agent targeted therapies, however, have modest activity. Identifying biomarkers that effectively determine response to targeted therapy remains a challenge. The next generation of clinical trials will focus on novel combinations and how to best utilize the advances that have been made in sequencing technology and bioinformatics. Although there is currently an immense body of data and many options for obtaining genomic characteristics of endometrial cancer, how to interpret and utilize this data is still being explored. This review will summarize the important trials that have led to the treatment options we have for advanced and/or recurrent endometrial cancer and discuss the important studies that have led to a better understanding of the distinctive molecular and genomic profiles within endometrial cancer. We will review the current status of biomarker-driven targeted therapy in endometrial cancer and the rationale behind ongoing clinical trials that are utilizing novel targeted agents.
引用
- Arend RC, Jones BA, Martinez A, et al. Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecol Oncol. 2018. PMID: 29843906. doi:10.1016/j.ygyno.2018.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。